Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2015

argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program

December 07, 2015

Workshop and webcast to occur at 12:00 pm ET today

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host a workshop and webcast to discuss new ARGX-110 data, in conjunction with the American Society of Hematology (ASH) Annual Meeting. The data on ARGX-110, a novel anti-CD70 therapeutic antibody, include topline clinical results in T-cell lymphoma (TCL) and preclinical data in acute myelogenous leukemia (AML). 

argenx reports third quarter 2015 financial results and provides business update

November 17, 2015

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the third quarter ended 30 September 2015. 

argenx to Present at Key Investor Conferences

October 29, 2015

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren and Chief Financial Officer, Eric Castaldi, will be participating in several upcoming investor conferences in November and December.

arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders

October 22, 2015

  • Potential breakthrough therapy for treatment of autoimmune crisis
  • Fourth arGEN-X drug candidate entering human trials in 6 years of operations

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the completion of the first human dosing of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis.

arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6

September 23, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies, has announced the first human dosing of Gerilimzumab, a novel monoclonal antibody neutralizing the IL-6 cytokine, for the treatment of autoimmune disorders including rheumatoid arthritis.

arGEN-X Announces Half-Year Results For 2015

August 25, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced its financial results for the first half of 2015 (six-month period ended June 30, 2015).

arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015

August 19, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces it will report its business update and financial results for the first half of 2015 on Wednesday, August 26, 2015.

arGEN-X to Present at Wedbush PacGrow Healthcare Conference

August 06, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 12, 2015 at 1:20pm ET.

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

July 30, 2015

  • Collaboration demonstrates potential of ARGX-110 in overcoming treatment resistance in chronic myelogenous leukemia (CML)
  • Preclinical results published in Science Translational Medicine

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors.

Change to the Board of Directors

July 15, 2015

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that non-executive director Michael B. Sheffery, representing Orbimed Advisors, will resign from the Board of Directors per 26 August 2015.

Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML

June 18, 2015

Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today presented preliminary results from an ongoing Phase I study of ARGX-110 in patients with T-cell lymphoma at the 13th International Conference on Malignant Lymphoma (Lugano, Switzerland; 17-20 June, 2015) in the ‘Novel Agents’ session.

arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT

June 01, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Jefferies 2015 Global Healthcare Conference in New York City (NY, USA) on Tuesday, 2 June 2015 at 8:00am EDT.

arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO

May 29, 2015

  • Safe dose established for next stage studies
  • Biological activity observed in MET-amplified cancer patient

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, will present the results of a Phase I, first-in-human dose escalation study of ARGX-111, a monoclonal antibody targeting c-Met in patients with solid tumors, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The company will present an abstract of the data on Saturday, May 30th, from 08:00am – 11:30am as part of the poster session on Development Therapeutics.

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

May 21, 2015

Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance in which they will collaborate to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions.

arGEN-X Awarded €1.5 Million IWT Grant to Advance the Application of NHance® Fc Modifications in Therapeutic Antibodies

May 19, 2015

Breda, The Netherlands / Ghent, Belgium, – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.

arGEN-X – First Quarter 2015 Financial Results and Business Update

May 15, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the first quarter ended 31 March 2015.

arGEN-X Announces Results of Annual General Meeting 2015

May 13, 2015

Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.

arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy

April 23, 2015

  • Results on ARGX-115 published in Science Translational Medicine indicating inhibition of immune checkpoint GARP in in vivo mouse model

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, and de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE) today announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint. These findings were published in the leading journal Science Translational Medicine and suggest potential for the antibody candidate in cancer immunotherapy.

arGEN-x N.V. Announces Changes to the Board of Directors

April 14, 2015

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the resignation of Non-executive Directors Dr. Bruno Montanari and Dr. Harrold van Barlingen from the Board of Directors per 13 May 2015.

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers

April 09, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has advanced ARGX-111, a best-in-class highly differentiated SIMPLE Antibody™ targeting c-MET driven malignancies, into the safety and efficacy expansion part of its Phase 1b study. The objective of the expansion cohort is to further characterize the safety of ARGX-111 in cancer patients with MET amplified tumors, and to evaluate efficacy signals in order to select the indications to be studied in Phase 2 clinical development.

arGEN-X Announces Annual General Meeting of Shareholders 13 May 2015

April 01, 2015

Breda, the Netherlands - arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Wednesday 13 May 2015.

arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results

March 18, 2015

Breda, the Netherlands / Ghent, Belgium arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and the consolidated full year results for 2014, which have been prepared in accordance with IFRS as adopted by the European Union.

arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

March 13, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.

arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015

March 11, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will report its fourth quarter business update and its full year 2014 financial results after market close on Wednesday, 18 March 2015.

arGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy

March 04, 2015

  • ARGX-115 re-activates immunity to cancer
  • First-in-class therapeutic antibody targeting GARP, a novel immune checkpoint
  • First candidate to be licensed under Company’s Innovative Access Program

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has exercised its option to exclusively license a first-in-class, preclinical therapeutic antibody candidate, now ARGX-115, to target GARP, a novel immune checkpoint with potential in cancer immunotherapy. ARGX-115 was discovered under arGEN-X’ Innovative Access Program with de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE).

arGEN-X Presents ARGX-111 at Targeted Anticancer Therapies

March 02, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, presented clinical potential of ARGX-111 in hematological malignancies and suppression of metastasis at Targeted Anticancer Therapies (TAT), Paris, France.

Lonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies

February 18, 2015

Basel, Switzerland, Ghent, Belgium and Breda, The Netherlands – Lonza, a global leader in biological manufacturing and arGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. The license secures long-term access for arGEN-X and its strategic partners to Lonza’s proprietary GS Xceed™ System for creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals.

arGEN-X Launches Innovative Access Program

January 12, 2015

  • Program extends reach of proprietary SIMPLE Antibody™ platform and creates potential for future value creation
  • First collaborations with U.S.-based biotech company active in dyslipidemia and the de Duve Institute in cancer immunotherapy

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has initiated its Innovative Access Program, providing its SIMPLE Antibody™ platform to academic centers of excellence and emerging biotech companies through collaboration. The goal of this program is to exploit the proven power of the SIMPLE Antibody™ platform in therapeutic areas complementary to arGEN-X’s strategic focus.